Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 5, 2012, Pages 1655-1660

  Rick, Ferenc G ^a,b   Schally, Andrew V ^a,b   Szalontay, Luca ^a   Block, Norman L ^a,b   Szepeshazi, Karoly ^a   Nadji, Mehrdad ^b   Zarandi, Marta ^a,b   Hohla, Florian ^a,b,c   Buchholz, Stefan ^a,b,d   Seitz, Stephan ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Advanced prostate cancer; Hormone refractory prostate cancer; Novel treatment; Prostatic cell death; Targeted therapy

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; JMR 132; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG;

ANDROGEN INDEPENDENT PROSTATE CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SERMORELIN;

EID: 84857137033     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120588109     Document Type: Article

References (48)

1. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Garcia JA, Rini BI (2011) Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. Cancer, 10.1002/cncr.26582.
3. O'Neill AJ, et al. (2011) Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 10:126.
4. Mostaghel EA, et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration- resistant prostate cancer. Cancer Res 67:5033-5041. (Pubitemid 46910214)
5. Scher HI, et al.; Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159.
6. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone- releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4:33-43. (Pubitemid 350291102)
7. Westley BR, May FE (1995) Insulin-like growth factors: The unrecognised oncogenes. Br J Cancer 72:1065-1066.
8. Havt A, et al. (2005) The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 102:17424-17429. (Pubitemid 41740882)
9. Schally AV (2008) New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 40:315-322.
10. Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566.
11. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P (1999) Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96:14894-14898. (Pubitemid 30019736)
12. Chopin LK, Herington AC (2001) A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 49:116-121. (Pubitemid 32937807)
13. Schally AV, Varga JL (2006) Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 9:163-170.
14. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL (2003) Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 100:1250-1255. (Pubitemid 36183988)
15. Stangelberger A, et al. (2005) Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 41:2735-2744. (Pubitemid 41607567)
16. Heinrich E, et al. (2008) Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 68:1763-1772.
17. Stangelberger A, et al. (2011) Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate, 10.1002/pros.21458.
18. Rick FG, et al. (2011) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71:736-747.
19. Stangelberger A, et al. (2005) Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 11:49-57. (Pubitemid 40075777)
20. Papadia A, et al. (2011) Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. Horm Metab Res 43:816-820.
21. Graff JR (2002) Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 6:103-113.
22. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284. (Pubitemid 29048852)
23. Uzgare AR, Kaplan PJ, Greenberg NM (2003) Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55:128-139. (Pubitemid 36444000)
24. Ghosh PM, Malik S, Bedolla R, Kreisberg JI (2003) Akt in prostate cancer: Possible role in androgen-independence. Curr Drug Metab 4:487-496. (Pubitemid 37536869)
25. Rodríguez-Berriguete G, et al. (2012) MAP kinases and prostate cancer. J Signal Transduct 2012:169170.
26. Hong SK, Kim JH, Lin MF, Park JI (2011) The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res 317:2671-2682.
27. Halmos G, et al. (2002) Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 87:4707-4714. (Pubitemid 35247065)
28. Rick FG, et al. (2011) Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 108:3755-3760.
29. Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV (2011) Growth hormone-releasing hormone: Not only a neurohormone. Trends Endocrinol Metab 22:311-317.
30. Barabutis N, Schally AV (2010) Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology. Cell Cycle 9:4110-4116.
31. Kiaris H, Koutsilieris M, Kalofoutis A, Schally AV (2003) Growth hormone-releasing hormone and extra-pituitary tumorigenesis: Therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opin Investig Drugs 12:1385-1394. (Pubitemid 36949695)
32. Siriwardana G, Bradford A, Coy D, Zeitler P (2006) Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 20:2010-2019. (Pubitemid 44286701)
33. Culig Z, et al. (1996) Regulation of prostatic growth and function by peptide growth factors. Prostate 28:392-405. (Pubitemid 26187724)
34. Putz T, et al. (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59:227-233. (Pubitemid 29062982)
35. Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19:5548-5557.
36. Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8:161-173. (Pubitemid 32947638)
37. Malik SN, et al. (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171. (Pubitemid 35177371)
38. Kreisberg JI, et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232-5236. (Pubitemid 39006542)
39. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A (2003) Androgen receptors in prostate cancer. J Urol 170:1363-1369. (Pubitemid 37108163)
40. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. (Pubitemid 46763022)
41. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ (2003) Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989. (Pubitemid 36460867)
42. Weber MJ, Gioeli D (2004) Ras signaling in prostate cancer progression. J Cell Biochem 91:13-25.
43. Paweletz CP, et al. (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981-1989.
44. Hassan S, Dobner PR, Carraway RE (2004) Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regul Pept 120:155-166. (Pubitemid 38726205)
45. Shimada K, et al. (2002) Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 35:127-137. (Pubitemid 35266059)
46. Zelivianski S, et al. (2003) ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107:478-485. (Pubitemid 37266470)
47. Hohla F, et al. (2009) GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 8:3149-3156.
48. Zarandi M, et al. (1994) Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91:12298-12302. (Pubitemid 24368652)